about
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaborationHIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersEfficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.Case-crossover analyses of air pollution exposure data: referent selection strategies and their implications for bias.Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.On quantifying the magnitude of confounding.Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.Rejoinder: Combining biomarkers to optimize patient treatment recommendationsCombining biomarkers to optimize patient treatment recommendations.Measuring the performance of markers for guiding treatment decisionsAssessing the value of risk predictions by using risk stratification tables.Commentary: Reporting standards are needed for evaluations of risk reclassificationLimitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized TrialsUse of placebos in Phase 1 preventive HIV vaccine clinical trialsAdjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve.Assessing treatment-selection markers using a potential outcomes framework.The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding TreatmentDesigning a study to evaluate the benefit of a biomarker for selecting patient treatment.Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)Identifying post-menopausal women at elevated risk for epithelial ovarian cancerPivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use.Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalitiesA framework for evaluating markers used to select patient treatment.Statistical analysis of air pollution panel studies: an illustration.New clinical trial designs for HIV vaccine evaluation.HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.Net reclassification indices for evaluating risk prediction instruments: a critical review.Net risk reclassification p values: valid or misleading?Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.Characterizing expected benefits of biomarkers in treatment selection.Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
P50
Q24289354-B2C80888-5A07-4FAF-8CE5-0547F44A7406Q24289476-44163418-B8EE-46F0-9244-7AA4FC3309EDQ28606620-E43B5478-EA2B-4D92-BDC1-24335FF877FEQ30578618-ED0692FF-9C79-4160-9A91-C1E6404EE084Q31011165-50494E99-606A-4253-9DDE-C813139EE0EDQ33614365-382058BB-64D1-4671-9993-175C0A5E9A06Q33904236-D1733488-CA99-4B9C-877E-6A4E072C9F3BQ34057942-514A6746-5F1E-4A9C-8618-DB0489114C81Q34117524-B9640423-2FBF-434F-9CC3-6C8E23A0CC7BQ34405131-C92BEB4D-E8E2-417D-9972-FA70EA8571A6Q34588757-1A383178-ED40-4972-B77F-3B0D5954D6B1Q34588910-CF908165-B09A-4A99-9A08-A4B080961EE4Q34897226-647B4FB8-D347-4117-A4C0-76032E4BC24DQ34969023-12E15712-4019-4963-A168-0ED7E9A0A747Q35165334-072B1AFC-7DE2-4AB6-AD87-3A6ED6BB855EQ35754449-7759C6EB-020D-4C11-BF4F-07CB801DDDD5Q35762443-F4E353AF-73FF-40DF-9AE4-E66102B285C1Q36011214-3A2359E1-25A9-4468-97F6-249B4670C6A9Q36021756-87D32B02-26B8-4791-A492-E9F8B74082A7Q36157844-0A68762D-CC4A-4A3E-8684-7F13A4787F70Q36173510-AE384E1B-ED38-4043-8F9E-2CD9F913733EQ36225623-C80BC964-ED23-4E39-8D34-18531FEB7E2BQ36247111-AA0B7F11-5EB8-4044-BD91-FF42E0372697Q36331643-3A6B68F1-F3FF-4CE3-8395-14A974E135A7Q36936929-220992F2-0E45-4E5A-9EFE-DF68F36AB851Q37050010-E55526B1-A43F-4EDD-B53B-56DEEA18B734Q37130232-3B0BF281-E6D1-42B5-926B-761351FA2CBBQ37187509-A6469926-080C-481D-9DC0-09652327050AQ37213295-34EDF2D3-45B3-434D-A82E-A4884A987699Q37258303-95C05480-6967-41D8-AD2C-3FCCCCB7ADCFQ37282240-0A548CA8-492C-4663-BB8E-62663D054F88Q37298748-CEA58A76-8FBA-41B1-92BA-37815FC06AC4Q37412300-117CEB92-B0DF-45DC-9E60-281D03FEBC13Q37413781-09AD4694-176B-4B12-866D-CBC960B9AAB3Q37569098-DB6C0604-9A06-4DB7-92D1-367B5006FB86Q37696697-72654DF3-1A8D-4536-9B0D-D243BA4344F6Q38381606-82814AD6-371A-4981-AF98-E11443E2EF21Q38716886-0F41DEF1-3EF9-4918-93BD-ADC0C50D4446Q38914707-DD9F4987-F392-4DA0-BDB4-30D3CC756E8FQ40533695-0D3CFA26-0C6E-48F5-A532-4C07157366C5
P50
name
Holly Janes
@ast
Holly Janes
@en
Holly Janes
@nl
type
label
Holly Janes
@ast
Holly Janes
@en
Holly Janes
@nl
prefLabel
Holly Janes
@ast
Holly Janes
@en
Holly Janes
@nl